Secarna Pharmaceuticals

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarnas mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company

Drug discovery,drug development,antisense oligonucleotides,bioinformatics,in vitro screening,in vivo screening,safety screening,rational drug design,and high throughput screening

Secarna pharmaceuticals operates in the Biotechnology research industry.

Secarna pharmaceuticals's revenue is 11m - 100m

Secarna pharmaceuticals has 11 - 50 employees.